MAGZEN® Effect on Recent Anxiety Reaction

MAGZEN® Effect on Recent Anxiety Reaction (STRESS2)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03602651

Acronym

STRESS2

Enrollment

110

Registered

2018-07-27

Start date

2019-11-08

Completion date

2021-05-14

Last updated

2021-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders

Brief summary

Multicentres, observational study, prospective, to evaluate the effect of MAGZEN® in the treatment of recent anxiety reaction.

Detailed description

107 patients suffering from recent anxiety reaction will be included in the study. They will be treated by MAGZEN® during 4 weeks and we will study the effect of this treatment on the evolution of their anxiety after the cure.

Interventions

OTHERHamilton-anxiety scale (HAM-A)

Evolution of anxiety disorders is evaluated by the Hamilton-anxiety scale (HAM-A)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* patient suffering from recent anxiety reaction * Hamilton-anxiety score ≥ 20 at inclusion * recent anxiety disorders (less than 3 months) not treated by pharmacological or psychological treatment

Exclusion criteria

* major depressive syndrome * anxiety disorders more than 3 months * anxiety due to death

Design outcomes

Primary

Measure	Time frame	Description
number of responders patients	4 weeks	number (%) of responders patients with a diminution of the HAM-A score ≥ 50 %

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026